Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
Astellas Pharma Global Development, Inc.
Other Non-Commercial Sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
This is a randomised trial with a experimental and active comparator arms. Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin. Participants in the Active Comparator arm will receive Midostaurin. Participants in the Experimental arm will receive Gliteritinib.